Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Naproxen Excluding the Dosage Syrup (Atc Code According to Who: M01ae02)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Capsaicin, Atc N01bx04 (Obg) for the Period September 1St, 2024 - August 31St, 2026

Market Investigation for the Acquisition of Genomic Profiling Tests for Hormone-Responsive Breast Cancer

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ranibizumab, Atc S01la04 (Obo) for the Period September 1St, 2024 - August 31St, 2026

Conclusion not Excluding Drug Discount Agreement. in Accordance with Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Fingolimod (Atc Code According to Who: L04ae01)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Olopatadine, Atc S01gx09 (Obg) for the Period September 1St, 2024 - August 31St, 2026

Conclusion not Excluding Drug Discount Agreement. in Accordance with Section 130A Paragraph 8 Sgb V by Means of an Open House Model for the Active Ingredient Epinephrine (Atc Code According to Who: C01ca24) in the Pre-Filled Syringe/Pen

Incontinence Products - Invitation to Dialogue Meetings

Imaging Diagnostic Tools - 2021

Request for Information: Oxygen Concentrators